Role of Yacrujjay tablet in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase 2
Completed
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2022/12/047884
- Lead Sponsor
- Dean and Principal Parul Institute of Ayurved
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Non-alcoholic fatty liver disease patient
Diagnosed by abdomen ultrasonic examination. Or
Fibroscan
a. Non-drinker
(Alcohol intake per week: female-under 140g,
male- under 210g) Or total abstainer or with
alcohol intake of less than 20g/ day for female
and less than 30 g/day for males.
2.Both diagnosed and newly diagnose patients of
NAFLD will be included
3.Subjective Criteria (Ajirna, Aruchi,
Atilalastrava, Chardi, Aadhmana, Vibhandha)
Exclusion Criteria
1.Pregnant or lactating females.
2.Alcoholic Fatty Liver Disease
Chronic Smoker, drug abusers, will be excluded
from study
3.Chronic illness like tuberculosis, acute
hepatitis and other life-threatening conditions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.fatty liver changes in USG between the groups (Pre and Post) <br/ ><br>2.Monthly Changes in NAFLD Symptoms over the 4 months of study treatment between the groupsTimepoint: Day 0 Day 30 Day 60 Day 90 Day 120
- Secondary Outcome Measures
Name Time Method 1. Monthly Changes in Body Mass index <br/ ><br>2. Changes in Fib 4 Index, NAFLD Fibrosis Score, LFT, CBC ,Lipid Profile And FibroscanTimepoint: Day 0 Day 30 Day 60 Day 90 Day 120